DAWN Next Earnings Date FAQ

On this page we presented the DAWN Next Earnings Date information for Day One Biopharmaceutical along with recent past earnings dates. For Q4 of 2024, DAWN reported earnings of -0.690/share, with the earnings report taking place on 2/25/2025. For Q3 of 2024, DAWN reported earnings of 0.380/share, with the earnings report taking place on 10/30/2024. For Q2 of 2024, DAWN reported earnings of -0.050/share, with the earnings report taking place on 7/30/2024. For Q1 of 2024, DAWN reported earnings of -0.720/share, with the earnings report taking place on 5/6/2024. For Q4 of 2023, DAWN reported earnings of -0.640/share, with the earnings report taking place on 2/26/2024. And with these past earnings dates behind DAWN, investors can look ahead to the next confirmed earnings date of 5/6/2025 after market close.

Any self directed investor who desires to keep tabs on the companies they own, can benefit from maintaining a calendar of next earnings dates for each stock in their porfolio, such as Day One Biopharmaceutical. When a company files its 10Q's with the SEC a mere four times a year, that certainly puts a lot of pressure on those four out of three hundred sixty five days! To say that earnings reports are important to Day One Biopharmaceutical shareholders would thus be an understatement! That's why we started the NextEarningsDate.com website, to make it easy for self directed investors to research Day One Biopharmaceutical next earnings dates as well as any other stock out there in our coverage universe, to see when the next DAWN earnings date — or any other stock — falls on the calendar. But we also present considerably more than just the next earnings date information alone, so we encourage you to explore the additional pages linked above to look up DAWN's past earnings as well, with pages for revenue and earnings history data, as well as earnings surprises as well. Thanks for visiting, and we hope you'll think of our site the next time you need to learn about the DAWN next earnings date.